RU2749591C1 - ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ АНТИТЕЛО, СПЕЦИФИЧНО СВЯЗЫВАЮЩЕЕСЯ С N-КОНЦОМ ЛИЗИЛ-тРНК-СИНТЕТАЗЫ, В КАЧЕСТВЕ ЭФФЕКТИВНОГО ИНГРЕДИЕНТА ДЛЯ ПРОФИЛАКТИКИ ИЛИ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, ОБУСЛОВЛЕННОГО МИГРАЦИЕЙ КЛЕТОК - Google Patents

ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ АНТИТЕЛО, СПЕЦИФИЧНО СВЯЗЫВАЮЩЕЕСЯ С N-КОНЦОМ ЛИЗИЛ-тРНК-СИНТЕТАЗЫ, В КАЧЕСТВЕ ЭФФЕКТИВНОГО ИНГРЕДИЕНТА ДЛЯ ПРОФИЛАКТИКИ ИЛИ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, ОБУСЛОВЛЕННОГО МИГРАЦИЕЙ КЛЕТОК Download PDF

Info

Publication number
RU2749591C1
RU2749591C1 RU2020113539A RU2020113539A RU2749591C1 RU 2749591 C1 RU2749591 C1 RU 2749591C1 RU 2020113539 A RU2020113539 A RU 2020113539A RU 2020113539 A RU2020113539 A RU 2020113539A RU 2749591 C1 RU2749591 C1 RU 2749591C1
Authority
RU
Russia
Prior art keywords
ser
gly
fibrosis
seq
leu
Prior art date
Application number
RU2020113539A
Other languages
English (en)
Russian (ru)
Inventor
Нам Хоон КВОН
Джин Янг ЛИ
Сунхоон КИМ
Original Assignee
БайоконТАК Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by БайоконТАК Ко., Лтд. filed Critical БайоконТАК Ко., Лтд.
Application granted granted Critical
Publication of RU2749591C1 publication Critical patent/RU2749591C1/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5029—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell motility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/9015—Ligases (6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
RU2020113539A 2017-09-15 2018-09-17 ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ АНТИТЕЛО, СПЕЦИФИЧНО СВЯЗЫВАЮЩЕЕСЯ С N-КОНЦОМ ЛИЗИЛ-тРНК-СИНТЕТАЗЫ, В КАЧЕСТВЕ ЭФФЕКТИВНОГО ИНГРЕДИЕНТА ДЛЯ ПРОФИЛАКТИКИ ИЛИ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, ОБУСЛОВЛЕННОГО МИГРАЦИЕЙ КЛЕТОК RU2749591C1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2017-0118917 2017-09-15
KR20170118917 2017-09-15
PCT/KR2018/010903 WO2019054819A1 (ko) 2017-09-15 2018-09-17 라이실 tRNA 합성효소 N-말단에 특이적으로 결합하는 항체를 유효성분으로 포함하는 면역세포 이동 관련 질환의 예방 또는 치료용 약학적 조성물

Publications (1)

Publication Number Publication Date
RU2749591C1 true RU2749591C1 (ru) 2021-06-15

Family

ID=65723723

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2020113539A RU2749591C1 (ru) 2017-09-15 2018-09-17 ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ АНТИТЕЛО, СПЕЦИФИЧНО СВЯЗЫВАЮЩЕЕСЯ С N-КОНЦОМ ЛИЗИЛ-тРНК-СИНТЕТАЗЫ, В КАЧЕСТВЕ ЭФФЕКТИВНОГО ИНГРЕДИЕНТА ДЛЯ ПРОФИЛАКТИКИ ИЛИ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, ОБУСЛОВЛЕННОГО МИГРАЦИЕЙ КЛЕТОК

Country Status (10)

Country Link
US (1) US11965038B2 (https=)
EP (1) EP3682898A4 (https=)
JP (1) JP7511241B2 (https=)
KR (1) KR102163465B1 (https=)
CN (1) CN111629752B (https=)
AU (1) AU2018332491B2 (https=)
BR (1) BR112020004935A8 (https=)
CA (1) CA3084461C (https=)
RU (1) RU2749591C1 (https=)
WO (1) WO2019054819A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019020166A2 (pt) 2017-03-27 2020-06-30 Medicinal Bioconvergence Research Center anticorpo que se liga especificamente a região n-terminal de lisil-trna sintetase exposta na membrana celular
CA3084461C (en) 2017-09-15 2025-06-17 Zymedi Co., Ltd. PHARMACEUTICAL COMPOSITION COMPRISING AN ANTIBODY THAT BINDS SPECIFICALLY TO THE N-TERMINAL END OF LYSYL TRANSFER RIBONUCLE ACID (NTRNA) SYNTHETASE AS AN ACTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF A DISEASE RELATED TO IMMUNE CELL MIGRATION
WO2020060156A1 (ko) * 2018-09-17 2020-03-26 재단법인 의약바이오컨버젼스연구단 세포 외막에 노출되는 라이실-tRNA 합성효소 N-말단 영역에 특이적으로 결합하는 항체

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011153277A2 (en) * 2010-06-01 2011-12-08 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases
RU2465330C1 (ru) * 2008-08-18 2012-10-27 Сеул Нэшнл Юниверсити Индастри Фаундейшн СПОСОБ ИНГИБИРОВАНИЯ МЕТАСТАЗИРОВАНИЯ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ ИЛИ МИГРАЦИИ ЗЛОКАЧЕСТВЕННЫХ КЛЕТОК ПОСРЕДСТВОМ СНИЖЕНИЯ КЛЕТОЧНОГО УРОВНЯ ЛИЗИЛ-тРНК-СИНТЕТАЗЫ (ВАРИАНТЫ), КОМПОЗИЦИЯ И ПРИМЕНЕНИЕ ВЕКТОРА ЭКСПРЕССИИ ИЛИ АНТИТЕЛА ПРОТИВ KRS ДЛЯ ИНГИБИРОВАНИЯ МЕТАСТАЗИРОВАНИЯ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ ИЛИ МИГРАЦИИ ЗЛОКАЧЕСТВЕННЫХ КЛЕТОК
US20130108630A1 (en) * 2009-12-11 2013-05-02 Jeffry Dean Watkins Amino acyl trna synthetases for modulating inflammation
US20160377619A1 (en) * 2013-12-30 2016-12-29 Medicinal Bioconvergence Research Center Anti-krs monoclonal antibody and use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9928136D0 (en) * 1999-11-29 2000-01-26 Rose Marlene L Organ rejection and associated conditions
KR100961392B1 (ko) 2008-04-15 2010-06-07 이화여자대학교 산학협력단 항체 파지 표면제시 라이브러리 제조방법, 상기 방법에의해 제조된 항체 파지 표면제시 라이브러리, 상기 항체파지 표면제시 라이브러리 유전자를 포함한 파지미드 벡터
AU2008360729A1 (en) 2008-08-18 2010-02-25 Seoul National University Industry Foundation Method for controlling cancer metastasis or cancer cell migration by modulating the cellular level of lysyl tRNA synthetase
KR101009501B1 (ko) * 2008-10-10 2011-01-18 서울대학교산학협력단 항-라이실 티알엔에이 합성효소 항체 및 항-라미닌 수용체 항체를 유효성분으로 포함하는 암 진단용 조성물
US11111396B2 (en) 2014-10-17 2021-09-07 C3 Nano, Inc. Transparent films with control of light hue using nanoscale colorants
US10050713B2 (en) 2015-03-02 2018-08-14 Futurewei Technologies, Inc. Optical transceiver using duplex media, self-homodyne detection (SHD), coherent detection, and uncooled laser
KR20180069146A (ko) 2016-12-14 2018-06-25 만도헬라일렉트로닉스(주) 주차 조향 보조 시스템 및 그 제어방법
BR112019020166A2 (pt) 2017-03-27 2020-06-30 Medicinal Bioconvergence Research Center anticorpo que se liga especificamente a região n-terminal de lisil-trna sintetase exposta na membrana celular
CA3084461C (en) * 2017-09-15 2025-06-17 Zymedi Co., Ltd. PHARMACEUTICAL COMPOSITION COMPRISING AN ANTIBODY THAT BINDS SPECIFICALLY TO THE N-TERMINAL END OF LYSYL TRANSFER RIBONUCLE ACID (NTRNA) SYNTHETASE AS AN ACTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF A DISEASE RELATED TO IMMUNE CELL MIGRATION

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2465330C1 (ru) * 2008-08-18 2012-10-27 Сеул Нэшнл Юниверсити Индастри Фаундейшн СПОСОБ ИНГИБИРОВАНИЯ МЕТАСТАЗИРОВАНИЯ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ ИЛИ МИГРАЦИИ ЗЛОКАЧЕСТВЕННЫХ КЛЕТОК ПОСРЕДСТВОМ СНИЖЕНИЯ КЛЕТОЧНОГО УРОВНЯ ЛИЗИЛ-тРНК-СИНТЕТАЗЫ (ВАРИАНТЫ), КОМПОЗИЦИЯ И ПРИМЕНЕНИЕ ВЕКТОРА ЭКСПРЕССИИ ИЛИ АНТИТЕЛА ПРОТИВ KRS ДЛЯ ИНГИБИРОВАНИЯ МЕТАСТАЗИРОВАНИЯ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ ИЛИ МИГРАЦИИ ЗЛОКАЧЕСТВЕННЫХ КЛЕТОК
US20130108630A1 (en) * 2009-12-11 2013-05-02 Jeffry Dean Watkins Amino acyl trna synthetases for modulating inflammation
WO2011153277A2 (en) * 2010-06-01 2011-12-08 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases
US20160377619A1 (en) * 2013-12-30 2016-12-29 Medicinal Bioconvergence Research Center Anti-krs monoclonal antibody and use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NECHUSHTAN H. et al. The physiological role of lysyl tRNA synthetase in the immune system // Advances in immunology. - 2009. - Vol. 103. - P. 1-27. *

Also Published As

Publication number Publication date
BR112020004935A8 (pt) 2022-07-05
AU2018332491B2 (en) 2022-04-14
CN111629752B (zh) 2024-03-29
KR102163465B1 (ko) 2020-10-07
CA3084461A1 (en) 2019-03-21
CA3084461C (en) 2025-06-17
US20210070880A1 (en) 2021-03-11
EP3682898A4 (en) 2021-09-29
BR112020004935A2 (pt) 2022-04-19
CN111629752A (zh) 2020-09-04
EP3682898A1 (en) 2020-07-22
WO2019054819A1 (ko) 2019-03-21
KR20190031189A (ko) 2019-03-25
AU2018332491A1 (en) 2020-04-30
US11965038B2 (en) 2024-04-23
JP2020534273A (ja) 2020-11-26
JP7511241B2 (ja) 2024-07-05

Similar Documents

Publication Publication Date Title
RU2765306C2 (ru) Антитело против в7-н3, его антигенсвязывающий фрагмент и их медицинское применение
JP7061875B2 (ja) アミロイドベータタンパク質に対するモノクローナル抗体及びその使用
KR101589135B1 (ko) 인간화 항-ｅｍａｐｉｉ 항체 및 이의 용도
CN109932509B (zh) 检测或抑制细胞外游离mg53的方法和用途
JP2010539969A (ja) ヒトヘプシジンに対して特異性を有する抗原結合タンパク質
JP2014530360A (ja) 診断マーカーとしてのｏｘＭＩＦ
RU2749591C1 (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ АНТИТЕЛО, СПЕЦИФИЧНО СВЯЗЫВАЮЩЕЕСЯ С N-КОНЦОМ ЛИЗИЛ-тРНК-СИНТЕТАЗЫ, В КАЧЕСТВЕ ЭФФЕКТИВНОГО ИНГРЕДИЕНТА ДЛЯ ПРОФИЛАКТИКИ ИЛИ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, ОБУСЛОВЛЕННОГО МИГРАЦИЕЙ КЛЕТОК
CN110603055B (zh) 与暴露于细胞膜上的赖氨酰-tRNA合成酶N末端区域特异性结合的抗体
WO2018182284A1 (ko) 세포 외막에 노출되는 라이실-tRNA 합성효소 N-말단 영역에 특이적으로 결합하는 항체
KR102114191B1 (ko) 세포 외막에 노출되는 라이실-tRNA 합성효소 N-말단 영역에 특이적으로 결합하는 항체
RU2781304C1 (ru) Антитело для специфического связывания с n-концевым доменом лизил-трнк-синтетазы, экспонированным на внеклеточной мембране
JP7453694B2 (ja) 細胞外膜に露出されるリシル－ｔＲＮＡ合成酵素のＮ－末端領域に特異的に結合する抗体
CN120137037A (zh) Cd3的特异性结合蛋白及其制备方法和应用
KR20160093502A (ko) 항 eprs 모노클로날 항체 및 이의 용도

Legal Events

Date Code Title Description
PC41 Official registration of the transfer of exclusive right

Effective date: 20211111